Description of COGNIVITRA

Coordinator: Instituto Pedro Nunes

Starting date: February 2019

Duration: 36 months

Total budget: € 773.072,54

Public contribution: € 581.015,28

Context/background of project

COGNIVITRA aims to fulfill this need through a unique solution that integrates cognitive training, physical and social stimulation, and will allow patients to increase session hours and overcome restrictions imposed by the availability of care resources (i.e. human and physical infrastructures). The extension from the clinic set up to the home environment will create fewer burdens for caregivers (formal and informal), because the tools needed for training sessions will be at home and become more available.

Objectives of the project

COGNIVITRA will develop a product that will provide solutions for cognitive training and extend it with physical stimulation for people at risk of developing cognitive impairment.

The potential longer term benefits

The trend for the upcoming years in terms of care and cure integration is characterized by shifting interventions to the home environment. COGNIVITRA will develop an ICT-based solution for cognitive vitality training at home. The growth in the incidence of different neurodegenerative diseases that leads to cognitive impairment is a growing problem worldwide. However, current care systems lack resources to address the growing number of patients requiring intervention.





Outputs of the project.

This document describes the achieved results during the execution of Task 1.1, as it is illustrated in the Description of Work. In particular, to involve organizations in the co-creation process, for the understanding phase, the requirements analysis is made and the end-users needs are evaluated using a special set of approaches provided by AAL (Active Assisted Living Association). This process will cover the User-centred Design and Value Proposition testing. For User-centred Design, we will adopt the “Persona” method, which directly involves all participants (end-users, end-user support organizations and consortium companies) with an intermediate effort rate. In this method, archetypes of each user are specified. For instance, to determine their demographic characteristics, it is reasonable to provide information such as lifestyle, interests, life class, affinity with technologies. For Value Proposition, testing it will be adopted the methods proposed by the Lean StartUp methodology to gather business requirements.

See full document

This document will present the requirements from the COGNIVITRA system, where these requirements are defined by possible end-users. The features identified in the Co-creation process will be detailed in this document. The results will serve as an aid to understanding and clarifying user' requirements and expectations of the system's functionality and to provide a basis for the definition of the different system functional features. For the conceptualization of requirements, we organize a design-thinking session, with focus groups to determine what is more important for all involved stakeholders in the process, i.e. not only technical partners and health care professionals that represent themselves but also informal caregivers and patients.More than inviting designers or engineers to contribute to the process, users, customers, patients and other stakeholders are crucial to confront the big issues and develop actionable ways to improve their current experiences or co-create a new solution.

See full document

This document reports the results of the work executed in “Task 3.3 - Pilots assessment”. This task will run in parallel with the pilots with the objective to collect the necessary information for the validation of the COGNIVITRA implemented solution. For the validation of the technology we plan to collect some information about its use, make questioners to the end-users, caregivers and others stakeholders to evaluate the social impact and the potential cost-effectiveness due to enhanced self-care, life-style and care management. COGNIVITRA will be validated from the perspective of the co-design methodology, relating these activities to the discovery of relevant information about the usability and effectiveness of the solutions. We will take as reference the guidelines provided by the AAL Program, identifying the method of “Cognitive Walkthrough” and “Co-Discovery” (suggested in the AAL Program toolbox for the testing phase). “Cognitive Walkthrough” is an analytical inspection method for prototypes evaluation from the end-user view. The “Co-Discovery” method can occur in parallel with the Cognitive Walkthrough, usually with two end users who, as they use the system, express what they are thinking out loud. In terms of the pilots' usability assessment tools, we will apply the instruments defined in D3.1. Additionally, this document also reports the main conclusions of pilot operation as defined in T3.2, which delivers D3.2 as a prototype. This document has two planned versions, one will be reporting on the results up to M15, and the final version at M36.

See full document

This document refers to the work carried out in “Task 4.1 - Dissemination strategy”. As described in the DoW, this task will run throughout the entire project duration and will have the main objective of developing and monitoring the execution of a dissemination strategy. The work is expected to be coordinated with the development of the exploitation and business strategy and the Intellectual Property Rights protection activities. Overall, we will assume as the most important aspect will be to maximize public awareness of COGNIVITRA's results. Note that, as this is a document that will result from an iterative process, it must be assumed that its content refers to a given period in time and describe the knowledge up to that moment. This mean, that it will be updated accordingly as new knowledge or initial assumption change (e.g. as a result of new information from AAL2Business activities, events, publication opportunities, etc.).

See full document

Our Partners

The team that compose COGNIVITRA.

Powered by

Contact us